Guidance
Update information
December 2021: We changed the strength of recommendation 1.3.15 from 'offer' to 'consider' to better reflect the balance between the benefits and harms associated with the use of metoclopramide and prochlorperazine. See the surveillance report for details.
May 2021: We amended recommendation 1.3.17 on the use of topiramate for migraine prophylaxis to include discussion of the potential benefits and risks of topiramate and the importance of effective contraception for women and girls of childbearing potential.
November 2015: We updated or made new recommendations on the prophylactic treatment of migraine. These recommendations are marked [2015].
We also made some changes to recommendation wording without an evidence review. These recommendations are marked as [2012, amended 2015]. These changes are:
-
Recommendations have been changed when standard practice or treatment options have changed since 2012.
-
Gabapentin has been removed from a recommendation, because it is no longer used for the treatment the recommendation covers.
-
Recommendations have been edited to align with changes in other recommendations or new recommendations that have been added.
Recommendations are marked as [2012] when the evidence was last reviewed in 2012.
Minor changes since publication
June 2024: We added links to the MHRA Drug Safety Update on topiramate use in pregnancy and in women and girls of childbearing potential.
May 2022: We added links to NICE's guideline on medicines associated with dependence or withdrawal symptoms in sections 1.2 and 1.3.
February 2020: A note was added to recommendation 1.3.17 on the potential risk of propranolol overdose in people with migraine who also have depression.
ISBN: 978-1-4731-1533-0